Maree Zinzley, Manager Approvals, of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”) that the following application has been made to register a trade name product under section 9(1) of the Act:
Trade Name: Solensia
Reference: A011914 – 1
Active Ingredient and Concentration:
Frunevetmab, an anti-Nerve Growth Factor (NGF) monoclonal antibody (mAb) 7mg/mL
Formulation Type: Aqueous solution for injection
General Use Claim:
For the treatment of pain associated with osteoarthritis in cats.
Any person may make a written submission to the director-general concerning this application.
Under sections 16 and 17 of the Act, a written submission:
- must state in full the reasons for making the submission;
- may state any decision sought on that application; and
- must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.
Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.
The following address is:
- where submissions on this application are to be sent;
- where requests for copies of the public information relating to the application can be sent;
- where public information relating to the application can be viewed; and
- the director-general’s address for service:
ACVM Group, Ministry for Primary Industries, Charles Fergusson Building, 34–38 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140.
The applicant’s address for service is:
Zoetis New Zealand Limited Level 4, 8 Mahuhu Crescent, Auckland Central, Auckland 1010. Postal Address: PO Box 2094, Shortland Street, Auckland 1140.
Dated at Wellington this 3rd day of November 2021.
MAREE ZINZLEY, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).